Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Oliver Strobel

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-5100-8449; OpenAlex author ID A5058627314. Sources: ClinicalTrials.gov.

Their work

Papers
135 (first author 4, last author 20)
Trials
1
Grants
0
Labs led
2
Collaborators
317
Papers, trials and grants by year

2011: 2 papers · 2012: 3 papers · 2013: 3 papers · 2014: 2 papers · 2015: 8 papers · 2016: 15 papers · 2017: 14 papers · 2018: 11 papers · 2019: 16 papers · 2020: 9 papers · 2021: 13 papers · 2022: 9 papers · 2023: 12 papers, 1 trial · 2024: 4 papers · 2025: 6 papers · 2026: 8 papers

Papers 50 of 135

  1. R0 Resection improves survival after multivisceral resection for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.isci.2026.117352↗
  2. International survey on neoadjuvant treatments in anatomically resectable pancreatic adenocarcinoma (INSPIRA): a real-life snapshot. Co-author DOI 10.1016/j.suronc.2026.102580↗
  3. The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer. Last author DOI 10.1016/s1470-2045(25)00714-4↗
  4. Para-aortic lymph nodes in oligometastatic pancreatic ductal adenocarcinoma - Authors' reply. Last author DOI 10.1016/s1470-2045(26)00249-4↗
  5. Neurogenic diarrhoea after superior mesenteric artery divestment or resection for pancreatic adenocarcinoma following preoperative chemotherapy: international … Co-author DOI 10.1093/bjsopen/zrag057↗
  6. Preoperative Surgical or Endoscopic Bile Duct Drainage in Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006407↗
  7. Neoadjuvant Treatment is a Risk Factor for Clinically Relevant Chyle Leak (ISGPS Grade B/C) After Pancreatic Cancer Resection: A Retrospective Cohort Study. Co-author DOI 10.1245/s10434-025-18698-4↗
  8. ASO Visual Abstract: Neoadjuvant Treatment is a Risk Factor for Clinically Relevant Chyle Leak (ISGPS Grade B/C) after Pancreatic Cancer Resection: A Retrospec… Co-author DOI 10.1245/s10434-025-18864-8↗
  9. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  10. Prognostic factors for very early recurrence after neoadjuvant treatment and curative resection in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.surg.2025.109647↗
  11. Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC): a prospective, multic… Co-author DOI 10.1016/s2468-1253(25)00056-1↗
  12. Validation of the PANAMA Score for Survival and Benefit of Adjuvant Therapy in Patients With Resected Pancreatic Cancer after Neoadjuvant FOLFIRINOX. Co-author DOI 10.1097/sla.0000000000006650↗
  13. Enhanced mutanome analysis towards the induction of neoepitope-reactive T-cell responses for personalized immunotherapy of pancreatic cancer. Co-author DOI 10.1136/jitc-2025-011802↗
  14. Standardized Approach to Superior Mesenteric Artery Resection for Locally Advanced Pancreatic Cancer. Last author DOI 10.3791/68465↗
  15. Prognostic Factors for Early Recurrence After Resection of Pancreatic Cancer: A Systematic Review and Meta-Analysis. Last author DOI 10.1053/j.gastro.2024.05.028↗
  16. Prognostic impact of resection margin status on survival after neoadjuvant treatment for pancreatic cancer: systematic review and meta-analysis. Co-author DOI 10.1097/js9.0000000000000792↗
  17. The Revised R Status is an Independent Predictor of Postresection Survival in Pancreatic Cancer After Neoadjuvant Treatment. Co-author DOI 10.1097/sla.0000000000005874↗
  18. Correction: Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer. Co-author DOI 10.18632/oncotarget.28527↗
  19. Smoking impairs the effect of neoadjuvant FOLFIRINOX on postresection survival in pancreatic cancer. Co-author DOI 10.1016/j.ejca.2023.113293↗
  20. Presence of low-grade IPMN at the pancreatic transection margin does not have prognostic significance after resection of IPMN-associated pancreatic adenocarcin… Last author DOI 10.1016/j.ejso.2022.08.003↗
  21. Defining oligometastatic pancreatic cancer: a systematic review and critical synthesis of consensus. Last author DOI 10.1016/j.esmoop.2023.102067↗
  22. Genetic ablation of ketohexokinase C isoform impairs pancreatic cancer development. Co-author DOI 10.1016/j.isci.2023.107368↗
  23. Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC. Co-author DOI 10.1038/s43018-023-00628-6↗
  24. Portal Vein Resection in Pancreatic Cancer Surgery: Risk of Thrombosis and Radicality Determine Survival. Co-author DOI 10.1097/sla.0000000000005444↗
  25. Oncological Outcome of Conversion Surgery After Preoperative Chemotherapy for Metastatic Pancreatic Cancer. Last author DOI 10.1097/sla.0000000000005481↗
  26. Transcriptome-based identification of tumor-reactive and bystander CD8+ T cell receptor clonotypes in human pancreatic cancer. Co-author DOI 10.1126/scitranslmed.adh9562↗
  27. Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study. Co-author DOI 10.1245/s10434-022-12387-2↗
  28. Resected Early-Onset Pancreatic Cancer: Practices and Outcomes in an International Dual-Center Study. Last author DOI 10.1245/s10434-022-12901-6↗
  29. ASO Author Reflections: Outcomes Support Aggressive Surgery for Early-Onset Pancreatic Cancer. Last author DOI 10.1245/s10434-022-12948-5↗
  30. [Corrigendum] Dexamethasone-induced inhibition of miR-132 via methylation promotes TGF-β-driven progression of pancreatic cancer. Co-author DOI 10.3892/ijo.2023.5543↗
  31. Refined prognostic staging for resected pancreatic cancer by modified stage grouping and addition of tumour grade. Last author DOI 10.1016/j.ejso.2021.07.020↗
  32. IPMN-associated pancreatic cancer: Survival, prognostic staging and impact of adjuvant chemotherapy. Last author DOI 10.1016/j.ejso.2021.12.009↗
  33. Glucocorticoid-induced microRNA-378 signaling mediates the progression of pancreatic cancer by enhancing autophagy. Co-author DOI 10.1038/s41419-022-05503-3↗
  34. Prognostic relevance of the revised R status definition in pancreatic cancer: meta-analysis. Co-author DOI 10.1093/bjsopen/zrac010↗
  35. Arterial Resection in Pancreatic Cancer Surgery: Effective After a Learning Curve. Co-author DOI 10.1097/sla.0000000000004054↗
  36. A Combination of Biochemical and Pathological Parameters Improves Prediction of Postresection Survival After Preoperative Chemotherapy in Pancreatic Cancer: Th… Co-author DOI 10.1097/sla.0000000000004143↗
  37. Actual Five-year Survival After Upfront Resection for Pancreatic Ductal Adenocarcinoma: Who Beats the Odds? Co-author DOI 10.1097/sla.0000000000004147↗
  38. A Pretreatment Prognostic Score to Stratify Survival in Pancreatic Cancer. Last author DOI 10.1097/sla.0000000000004845↗
  39. Patient-specific modeling of stroma-mediated chemoresistance of pancreatic cancer using a three-dimensional organoid-fibroblast co-culture system. Last author DOI 10.1186/s13046-022-02519-7↗
  40. Genome-wide scan of long noncoding RNA single nucleotide polymorphisms and pancreatic cancer susceptibility. Co-author DOI 10.1002/ijc.33475↗
  41. [Surgery for periampullary pancreatic cancer]. Last author DOI 10.1007/s00104-021-01462-1↗
  42. Clinical presentation and prognosis of adenosquamous carcinoma of the pancreas - Matched-pair analysis with pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.ejso.2021.02.011↗
  43. Periarterial divestment in pancreatic cancer surgery. Co-author DOI 10.1016/j.surg.2020.08.030↗
  44. Single-cell analysis of patient-derived PDAC organoids reveals cell state heterogeneity and a conserved developmental hierarchy. Co-author DOI 10.1038/s41467-021-26059-4↗
  45. Lack of association of CD44-rs353630 and CHI3L2-rs684559 with pancreatic ductal adenocarcinoma survival. Co-author DOI 10.1038/s41598-021-87130-0↗
  46. Technical advances in surgery for pancreatic cancer. Co-author DOI 10.1093/bjs/znab133↗
  47. Associations between pancreatic expression quantitative traits and risk of pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/carcin/bgab057↗
  48. Prognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003270↗
  49. Deep molecular characterization linked to drug response profiling of pancreatic ductal adenocarcinoma using patient-derived organoids Last author DOI 10.1101/2021.08.26.457743↗
  50. Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction. Co-author DOI 10.1136/jmedgenet-2020-106961↗

Trials 1

  1. The HELPP Score: A Pretreatment Score to Predict Survival in Pancreatic Cancer Study director NCT05752812↗

Closest collaborators

The 25 strongest of 317 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Markus Wolfgang Büchler · 64 shared papers, 2011–2026 · strength 7.20
  2. Thilo Hackert · 64 shared papers, 2011–2026 · strength 6.03
  3. Carl-Stephan Leonhardt · 21 shared papers, 2018–2026 · strength 4.40
  4. Thomas P. Hank · 28 shared papers, 2015–2026 · strength 4.39
  5. Ulla Klaiber · 16 shared papers, 2018–2026 · strength 2.65
  6. John P. Neoptolemos · 17 shared papers, 2016–2023 · strength 1.38
  7. Gerald W. Prager · 5 shared papers, 2023–2026 · strength 1.35
  8. Martin Loos · 7 shared papers, 2021–2026 · strength 1.35
  9. Klaus Sahora · 6 shared papers, 2021–2025 · strength 1.33
  10. Nathalia A. Giese · 16 shared papers, 2015–2024 · strength 1.20
  11. Martin Schindl · 5 shared papers, 2021–2025 · strength 0.96
  12. Jörg Kaiser · 7 shared papers, 2018–2023 · strength 0.95
  13. Martin A. Schneider · 6 shared papers, 2020–2026 · strength 0.91
  14. Mohammed Al‐Saeedi · 4 shared papers, 2022–2026 · strength 0.91
  15. Matthias M. Gaida · 10 shared papers, 2011–2022 · strength 0.82
  16. Ingrid Herr · 7 shared papers, 2015–2024 · strength 0.76
  17. Solange Le Blanc · 5 shared papers, 2021–2024 · strength 0.75
  18. Willem Niesen · 6 shared papers, 2017–2022 · strength 0.71
  19. Andrew Louis Warshaw · 4 shared papers, 2022–2025 · strength 0.69
  20. Motaz Qadan · 4 shared papers, 2022–2025 · strength 0.69
  21. Keith D. Lillemoe · 4 shared papers, 2022–2025 · strength 0.69
  22. Benedict Kinny‐Köster · 3 shared papers, 2023–2026 · strength 0.68
  23. Nathalie Bauer · 6 shared papers, 2015–2024 · strength 0.62
  24. Rienk Offringa · 6 shared papers, 2015–2025 · strength 0.59
  25. André L. Mihaljević · 5 shared papers, 2017–2022 · strength 0.55

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.